📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

A targeted, low-throughput compound screen in a Drosophila model of neurofibromatosis type 1 identifies simvastatin and BMS-204352 as potential therapies for autism spectrum disorder (ASD) (2022)

First Author: Dyson A

Attributed to: Homeostatic control of neuron excitability funded by BBSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1101/2022.11.11.516139

Publication URI: http://dx.doi.org/10.1101/2022.11.11.516139

Type: Preprint